AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01646814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PL2200
Description: PL2200, containing 325 mg aspirin active ingredient
Study NCT01646814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin tablets
Description: 325 mg aspirin tablets (USP)
Study NCT03522961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin Prophylaxis/Placebo
Description: Drug: Nitrofurantoin Drug: Placebo
Study NCT03522961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry capsules
Description: Drug: TheraCran® One Cranberry capsules
Study NCT00039013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC2993
Description: Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
Study NCT00039013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC2993
Description: Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5 mcg (0.02 mL) for 4 weeks / AC2993 10 mcg (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
Study NCT00039013 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Lead In (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
Study NCT01501136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase)
Description: DDP 20 mg/m2,ivgtt（intravenously guttae）, d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required. Completion of chemotherapy is followed by radiotherapy 50Gy.Efficacy was evaluated every two cycles.
Study NCT01501136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VIPD（cisplatin，Etoposide，Ifosfamide， dexamethasone，Mesna）
Description: DDP,33mg/m2,ivgtt（intravenously guttae）,d1-3；VP-16,100mg/m2,ivgtt,d1-3；IFO,1.2g/m2,ivgtt,d1-3；DEX,40mg,ivgtt,d1-4；Mesna,0、4、8h after IFO,240mg/m2,iv,d1-3.Every 21 days for one cycle and three cycles are required. Completion of chemotherapy is followed by radiotherapy 50Gy.Efficacy was evaluated every two cycles.
Study NCT01501136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gemcitabine,pegaspargase,cisplatin,dexamethasone
Description: Radiotherapy 50Gy is followed by chemotherapy(DDP 20 mg/m2,ivgtt（intravenously guttae）,d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required ).Efficacy was evaluated every two cycles.
Study NCT01501136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cisplatin,Etoposide,Ifosfamide,dexamethasone,Mesna
Description: Radiotherapy 50Gy is followed by chemotherapy(DDP,33mg/m2,ivgtt（intravenously guttae）,d1-3；VP-16,100mg/m2,ivgtt,d1-3；IFO,1.2g/m2,ivgtt,d1-3；DEX,40mg,ivgtt,d1-4；Mesna,0、4、8h after IFO,240mg/m2,iv,d1-3.Every 21 days for one cycle and three cycles are required ).Efficacy was evaluated every two cycles.
Study NCT01501136 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Suitable type intensity-modulated radiation therapy(IMRT)50Gy
Study NCT01811381 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic yoga
Description: Each week, subjects will attend two one hour aerobic yoga classes under the supervision of certified yoga instructors and complete two 30 minute aerobic yoga practice sessions at home. If proficient, subjects will take a live-video conference remote class, HIPAA approved SecureVideo classes. Modification of consent has been approved.
Study NCT01811381 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aerobic yoga
Description: Each week, subjects will attend two one hour aerobic yoga classes under the supervision of certified yoga instructors and complete two 30 minute aerobic yoga practice sessions at home. If proficient, subjects will take a live-video conference remote class, HIPAA approved SecureVideo classes. Modification of consent has been approved.
Study NCT01811381 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: non aerobic yoga
Description: Subjects will take two non-aerobic (stretching) classes weekly as well as practice two 30 minutes yoga routines at home weekly.~Each week, subjects will attend two one hour non-aerobic yoga classes under the supervision of certified yoga instructors and complete two 30 minute non-aerobic yoga practice sessions at home.
Study NCT01811381 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will take 4 capsules x BID of placebo
Study NCT01811381 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take 4 capsules x BID of placebo
Study NCT01332019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon beta-1a
Description: Administered as specified in the treatment arm
Study NCT02535078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebentafusp (IMCgp100)
Description: soluble gp100-specific T cell receptor with anti-CD3 scFV
Study NCT00604435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel and epirubicin
Description: docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 60 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, totally 3 cycles
Study NCT00604435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel and epirubicin plus endostatin
Description: docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 60 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostatin 7.5mg/m2, IV (in the vein) on 1st to 14th days of each 21 day cycle; every 3 weeks, totally 3 cycles
Study NCT02720653 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic sinus surgery
Study NCT04043715 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transcutaneous spinal stimulation
Description: Physical therapy to improve standing and walking
Study NCT04043715 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Epidural spinal stimulation
Description: Physical therapy to improve standing and walking
Study NCT00745953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan 320mg PO daily for 8 months
Study NCT00745953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 25mg PO daily for 8 months
Study NCT02637440 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FFR guided PCI
Description: Patients undergo Fractional Flow measurement (FFR) followed by PCI, if the FFR is less than 0.8
Study NCT02637440 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angio guided PCI
Description: Patients receive PCI without FFR measurement
Study NCT00039013 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
Study NCT03711877 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scalp cooling system
Description: Scalp cooling was initiated 30 minutes prior to each chemotherapy cycle, with scalp temperature maintained at 3°C (37°F) throughout chemotherapy and for 90 minutes to 120 minutes afterward. Temperature of scalp cooling system can be controlled constantly, the effect of reducing scalp temperature maybe better and patient tolerance maybe better. Meanwhile, there is a higher likelihood of hair retention due to a tight fit in scalp cooling system.
Study NCT03711877 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cold cap
Description: The operation of chemical cold cap is convenient and the price was low, and the economic burden of patients was not increased. But it is necessary to replace the cold cap periodically during chemotherapy, and the temperature during chemotherapy is difficult to keep constant.
Study NCT04256304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PHEinAction-Personalized Patient Engagement Plan
Description: The intervention includes two face-to-face sessions, a telephone consultation, and written home-based exercises. The first session aims to promote an awareness of patients with diabetes management, define an action plan to encourage engagement, introduce the patient to follow their strategy for the next four weeks, and encourage them to adopt the instruments with home-based exercises to reach their specified health goals. Two weeks after the first interview session, the researcher will provide telephone consultation to check the patient for their progress and support them to maintain motivation. The second session will include collecting patient's experiences and discussing the home-based exercises, re-determining the patient health engagement phase through the PHE-s®, discussing the personalized care goals by providing feedback aiming to support improvements, and setting a new engagement goal with the current status and encouraging the patient to maintain the health engagement plan.
Study NCT02797639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Co-PID
Description: The program was carried out by the school occupational therapist and homeroom teachers. The Co-PID had two phases. The first phase was a 1.5 hour in-service meeting that focused on the concept of Participation.~In the second phase of the Co-PID intervention, a collaborative consultation model was used. It included eight 45-minute consultation meetings, which took place every other week over a 3-months period. The meetings took place between the occupational therapist and each teacher, with the purpose of brainstorming; thinking of activities that the teacher could implement during the lessons for enhancing participation among the students.
Study NCT02797639 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IS
Description: IS group included three meetings, a 1.5 hour in-service meeting focusing on the concept of participation, and two more workshop meetings aimed at sharing teachers' experience.
Study NCT01957709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01957709 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Gamma
Description: Given subcutaneously weekly for four weeks prior to surgery.
Study NCT03587584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal bupivacaine
Description: Experimental
Study NCT03587584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Active Comparator
Study NCT04142749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oltipraz
Description: Total 90mg, By mouth, TID
Study NCT04142749 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Total 90mg, By mouth, TID
Study NCT01111019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (r-hGH)
Description: Subjects will receive a single subcutaneous injection of recombinant human growth hormone (r-hGH) equivalent to a dose of 0.057 milligram per kilogram per day (mg/kg/day). The dose will be subsequently adjusted during the trial and subjects will be treated for at least 3 years or until near final height is reached.
Study NCT01346774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cranberry powder capsules
Description: 2 cranberry powder capsules twice a day
Study NCT03028584 — intervention group
Intervention type: BEHAVIORAL
Intervention: Survey
Description: Subjects (cancer patients and clinicians) will complete up to 2 surveys.
Study NCT04234763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategies to lower postprandial hyperglycemia in T2D patients
Description: T2D patients will undergo a 14-day chronic feeding trial intervention where the strategies to lower postprandial hyperglycemia will be educated. For example, to control portion of carbohydrate, incorporate low GI food and diabetes-specific formula, promote physical activity and practice consistent meal timing. After that, patients will undergo MCT again to evaluate the difference before and after the intervention.
Study NCT04234763 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Assess nutritional status and no active intervention is conducted.
Study NCT03746808 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EMA + App/Treatment Messages
Description: This study will develop and test a just-in-time adaptive intervention to reduce alcohol use among homeless adults. Phase I will use smartphones and passive sensing to monitor geolocation, psychosocial variables (e.g., stress, urge to drink), and alcohol use in a group of 80 homeless adults with an AUD who are enrolled in shelter-based treatment. Phase II will use this information to create a risk algorithm and tailored treatment messages that anticipate and intervene to prevent alcohol use.
Study NCT03746808 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: EMA + App/Treatment Messages
Description: This study will develop and test a just-in-time adaptive intervention to reduce alcohol use among homeless adults. Phase I will use smartphones and passive sensing to monitor geolocation, psychosocial variables (e.g., stress, urge to drink), and alcohol use in a group of 80 homeless adults with an AUD who are enrolled in shelter-based treatment. Phase II will use this information to create a risk algorithm and tailored treatment messages that anticipate and intervene to prevent alcohol use.
Study NCT04145869 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cholangiography
Description: All patients will be subjected to intraoperative fluorescent and concommitant X-ray cholangiography
Study NCT01346774 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder capsules
Description: 2 placebo capsules twice a day
Study NCT00630890 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation and Cyberknife radiosurgery boost and capecitabine
Description: External Beam Radiation to 45 Gy Stereotactic Body Radiotherapy with Cyberknife to 20 Gy in 5 fractions dose escalation to 25 Gy in 5 fractions, and then 30 Gy in 5 fractions Capecitabine 825 mg/m2 q12 hours taken orally 5 days per week
Study NCT00409318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: 50 mg SC q week
Study NCT00409318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC q week
Study NCT02246439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RHB-102
Description: RHB-102, Bimodal Release Ondansetron Tablets
Study NCT02246439 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo
Study NCT02706782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAI-meso-CART
Description: TAI as a local drug delivery pathway, so that more T cells gathered at the tumor site, less T cells to migrate to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And meso-CART is a 2nd CAR, with mesothelin as target protein, 4-1BB as co- stimulator
Study NCT02255682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Study NCT02255682 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin
Study NCT02255682 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Q10
Study NCT03858738 — intervention group
Intervention type: DEVICE
Intervention: Thermographic breast examination performed by Braster device
Description: Patient undergo contact thermography examination with the use of liquid crystal contact thermography device- Braster.
Study NCT03595631 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week.
Study NCT03595631 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy plus Neurodynamic
Description: Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week. In addition, they will also receive bilateral nerve slider neurodynamic interventions targeting the median, ulnar and radial nerves.
Study NCT01873105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Team Educational Intervention
Description: AHRQ TeamStepps processes will be used to redesign health team discharge communication processes and an educational intervention for health care team members
Study NCT03055091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Xylitol syrup
Description: Each dose will be 5 mL of 400 g/L and subjects will receive Three to 5 doses will be given each day.
Study NCT03055091 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each dose looks and tastes like the xylitol syrup but it is not microbial. Each dose will be 5 mL of 300 g/L of sorbitol. Three to 5 doses will be given each day.
Study NCT04123730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fixed-dose compared to variable oxygen flow supplementation during walking
Description: At day 1 the patients will perform Walk A and Walk B in a random order:~Walk A: The patients will perform a Endurance Shuttle Walk Tests (ESWT) with the fixed-dose (FOT). O2matic will monitor pulse rate and saturation continuously during the test.~Walk B: The patients will perform a Endurance Shuttle Walk Tests (ESWT) with a variable oxygen flow (AOT) depending on the saturation. O2matic will monitor pulse rate and saturation continuously during the test, and adjust oxygen flow depending on the saturation.~At day 2 the patients will perform two 6 minutes walking (MWT) test in random order:~Walk C: A 6 MWT with FOT Walk D; A 6 MWT with AOT
Study NCT04123730 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fixed-dose compared to variable oxygen flow supplementation during walking
Description: At day 1 the patients will perform Walk A and Walk B in a random order:~Walk A: The patients will perform a Endurance Shuttle Walk Tests (ESWT) with the fixed-dose (FOT). O2matic will monitor pulse rate and saturation continuously during the test.~Walk B: The patients will perform a Endurance Shuttle Walk Tests (ESWT) with a variable oxygen flow (AOT) depending on the saturation. O2matic will monitor pulse rate and saturation continuously during the test, and adjust oxygen flow depending on the saturation.~At day 2 the patients will perform two 6 minutes walking (MWT) test in random order:~Walk C: A 6 MWT with FOT Walk D; A 6 MWT with AOT
Study NCT03058133 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: fMRI study
Description: Functional brain activations of face-voice processing during a gender task
Study NCT03119168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simethicone Solution
Description: Patients will be assigned randomly to take Simethicone Solution plus polyethylenglycol
Study NCT03119168 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylenglycol
Description: Patients in this arm will be randomly assigned to take polyethylenglycol as their regular bowel preparation
Study NCT02170844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS
Study NCT02170844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of BIBR 1048 MS
Study NCT02042287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal lactic acid and glycogen gel
Description: Medical device (registration number: 10-355-717, first licensed 12.08.2010)
Study NCT02042287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Oral antibiotic
Study NCT03661957 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non grafted maxillary sinus floor elevation with simultaneous implant placement
Description: lateral window for sinus elevation ,membrane elevation ,implant placement , membrane for window closure
Study NCT03661957 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: using short dental implants for posterior atrophic maxilla
Description: placement of short dental implant with bone height below 8mm
Study NCT04372004 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: diagnostic tests for COVID-19 infection
Description: Compare the efficacy of diagnostic tests for COVID-19 infection in detecting antibodies and viral-RNA
Study NCT02372253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Study NCT02372253 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00694447 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Study NCT01930318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parecoxib
Description: 4 groups: PCA,Placebo,Placebo-PCA for 2 days after operation, i.v placebo in 2 days after surgery and oral placebo in the day 3 to day 5 after surgery; PCA,placebo,tramadol-PCA for 2 days after operation, i.v placebo in 2 days after surgery, and oral tramadol(0.1g t.i.d.) in the day 3 to day 5 after surgery;PCA,parecoxib,placebo-PCA for 2 days after operation, i.v parecoxib(40mg b.i.d.) in 2 days after surgery,and oral placebo in the day 3 to day 5 after surgery;PCA,parecoxib,celecoxib-PCA for 2 days after operation,i.v parecoxib(40mg b.i.d.) in 2 days after surgery and oral celecoxib(0.2g b.i.d.) in the day 3 to day 5 after surgery